We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

66 hedge funds and large institutions have $27.4M invested in Matinas BioPharma in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% more ownership

Funds ownership: 0.24% → 0.25% (+0.01%)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

1% less funds holding

Funds holding: 67 → 66 (-1)

18% less capital invested

Capital invested by funds: $33.5M → $27.4M (-$6.11M)

Holders
66
Holders Change
-1
Holders Change %
-1.49%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
12
Reduced
13
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.68M
2
SIG
Sargent Investment Group
Maryland
+$410K
3
CCM
Courage Capital Management
Tennessee
+$214K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$205K
5
SWM
Spire Wealth Management
Virginia
+$169K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$967K
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$221K
3
Jane Street
Jane Street
New York
-$211K
4
VF
Virtu Financial
New York
-$156K
5
PAG
Private Advisor Group
New Jersey
-$75.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$72K +$18.2K +341 +31%
Qube Research & Technologies (QRT)
27
Qube Research & Technologies (QRT)
United Kingdom
$60K +$63.6K +1,190 New
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$60K +$63.7K +1,191 New
IFG
29
Investors Financial Group
Minnesota
$51K -$32.1K -600 -38%
SCP
30
Sandhill Capital Partners
New York
$50K -$21.4K -400 -29%
Goldman Sachs
31
Goldman Sachs
New York
$47K +$49.7K +929 New
MFS
32
Mirabella Financial Services
United Kingdom
$46K +$48.2K +902 New
JP Morgan Chase
33
JP Morgan Chase
New York
$45K – – –
TSS
34
Two Sigma Securities
New York
$37K -$38.3K -716 -49%
Rafferty Asset Management
35
Rafferty Asset Management
New York
$35K +$36.8K +688 New
JMPWA
36
JP Morgan Private Wealth Advisors
California
$32K – – –
Osaic Holdings
37
Osaic Holdings
Arizona
$31K +$5.35K +100 +19%
Victory Capital Management
38
Victory Capital Management
Texas
$30K -$802 -15 -2%
CWM
39
CCG Wealth Management
California
$30K – – –
Commonwealth Equity Services
40
Commonwealth Equity Services
Massachusetts
$29K -$25K -468 -45%
DAS
41
Dynamic Advisor Solutions
Arizona
$26K +$2.99K +56 +12%
IWC
42
Integrated Wealth Concepts
Massachusetts
$25K -$641 -12 -2%
NWMG
43
National Wealth Management Group
Ohio
$24.1K +$25.6K +478 New
MA
44
MONECO Advisors
Connecticut
$22K – – –
Wells Fargo
45
Wells Fargo
California
$21K +$1.07K +20 +5%
CSS
46
Cubist Systematic Strategies
Connecticut
$20K +$7.7K +144 +57%
OAM
47
Occidental Asset Management
California
$20K +$21.4K +400 New
NRS
48
Neville Rodie & Shaw
New York
$18K – – –
SBWIC
49
Schaper Benz & Wise Investment Counsel
Wisconsin
$14K – – –
RJA
50
Raymond James & Associates
Florida
$14K +$14.4K +270 New
1
2
3 4

MTNB Hedge Fund Activity: Q4 2021 in Review

66 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2021, worth a combined $27.4M — down 18% from $33.5M a quarter earlier.

Fund positioning in MTNB was balanced in Q4 2021: 11 funds opened new positions, 11 closed out, 12 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $1.68M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $967K sold.

  • 66 institutional investors held Matinas BioPharma (MTNB) as of Q4 2021, down from 67 in Q3 2021.
  • Funds reported $27.4M of Matinas BioPharma stock for Q4 2021, down 18% quarter-over-quarter.
  • 11 funds opened new Matinas BioPharma positions in Q4 2021 and 11 closed out, a net change of 0 holders.
  • The largest Matinas BioPharma buyer in Q4 2021 was BlackRock, an estimated $1.68M added.
  • The largest Matinas BioPharma seller in Q4 2021 was GSA Capital Partners, an estimated $967K sold.

Based on aggregated 13F filings for Q4 2021.